Ropenia300 mcg/0.5 ml

Ropenia is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of neutrophils (a type of white blood cell) in patients at risk of infection due to low neutrophil counts (neutropenia).

Established/FDA-approved indications

• Chemotherapy-induced neutropenia: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer chemotherapy.
• Acute myeloid leukemia (AML): To reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy.
• Bone marrow transplantation (BMT): To reduce the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplant.
• Peripheral blood progenitor cell (PBPC) mobilization: To mobilize hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
• Severe chronic neutropenia (SCN): For chronic administration to reduce the incidence and duration of infection-related sequelae (fever, infections, oral ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.
• Acute radiation syndrome: To increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).

Ropenia is not indicated for mobilizing peripheral blood progenitor cells in patients with cancer whose malignancy has bone marrow involvement, and its safety and efficacy have not been established for use in chronic myeloid leukemia or myelodysplastic syndrome.

Each vial/pre-filled syringe of Filgrastim injection contains recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF), commonly supplied as 300 mcg/0.5 mL or 120 mcg/0.2 mL solution for injection. It is produced in Escherichia coli (E. coli) using recombinant DNA technology. Excipients typically include acetate buffer, sorbitol, polysorbate 80, and water for injection; formulations may vary slightly by manufacturer.

Ropenia is a biosynthetic (recombinant) form of human granulocyte colony-stimulating factor (G-CSF). It regulates the production, maturation, and functional activation of neutrophils within the bone marrow. By binding to specific receptors on precursor cells, Ropenia stimulates the proliferation and differentiation of neutrophil progenitors, increasing the number of circulating neutrophils available to fight infection.

Ropenia is administered by subcutaneous injection or intravenous infusion and is widely used in oncology and hematology to shorten the duration of chemotherapy-induced neutropenia and reduce the risk of serious infection.

Ropenia belongs to the class of hematopoietic (blood cell) growth factors, specifically the granulocyte colony-stimulating factors (G-CSF), used as supportive care agents in oncology and hematology.

Mechanism of action

Filgrastim is a recombinant analogue of endogenous human G-CSF. It binds to specific cell-surface G-CSF receptors on myeloid progenitor cells in the bone marrow, triggering intracellular signaling pathways (via JAK/STAT) that stimulate proliferation, differentiation, and maturation of neutrophil precursors into mature, functional neutrophils. Filgrastim also enhances the phagocytic and chemotactic activity of mature neutrophils and stimulates their release from the bone marrow into the peripheral circulation.

Pharmacokinetics

After subcutaneous injection, Filgrastim is absorbed with peak serum concentrations typically reached within 2-8 hours; bioavailability after subcutaneous dosing is approximately 60-70%. It is cleared through both a saturable (receptor-mediated, neutrophil-dependent) pathway and non-saturable renal clearance, with an elimination half-life of approximately 3.5 hours. Clearance decreases as neutrophil counts rise because more receptor-mediated uptake occurs.

Ropenia is given as a subcutaneous injection (into the fat layer under the skin of the abdomen, thigh, or upper arm) or as an intravenous infusion, depending on the indication and clinical setting. It should be administered by, or under the supervision of, a qualified healthcare professional, although self-injection at home may be taught to appropriately trained patients/caregivers for chronic use (e.g., severe chronic neutropenia). Allow the vial/syringe to warm to room temperature for about 30 minutes before injection; do not shake vigorously. Rotate injection sites to reduce local irritation. Do not administer Ropenia within 24 hours before or after cytotoxic chemotherapy.

No formal, extensive drug-interaction studies have been conducted with Ropenia. The following interactions are clinically relevant:

• Lithium: Lithium may potentiate the neutrophil-releasing effects of Ropenia; although not formally studied, patients on concurrent lithium therapy should have neutrophil counts monitored more frequently.
• Cytotoxic chemotherapy/radiation therapy: Because rapidly dividing myeloid cells may be more sensitive to cytotoxic chemotherapy, Ropenia should not be administered in the period from 24 hours before to 24 hours after administration of cytotoxic chemotherapy, and concurrent use with radiation therapy has not been evaluated and is not recommended.

Very common

• Bone pain (a characteristic, dose-related effect of increased bone marrow activity)
• Musculoskeletal/back pain
• Injection site reactions (redness, swelling, pain)
• Headache
• Fever, fatigue
• Nausea

Common

• Elevated alkaline phosphatase, uric acid, and lactate dehydrogenase (usually mild and reversible)
• Transient decreases in blood pressure
• Epistaxis (nosebleed), rash

Rare but serious (seek prompt medical attention)

• Splenic rupture: including fatal cases; presents as left upper abdominal or shoulder-tip pain — requires urgent evaluation.
• Acute respiratory distress syndrome (ARDS): presents as fever, lung infiltrates, and respiratory distress.
• Serious allergic reactions/anaphylaxis: rash, urticaria, facial swelling, breathing difficulty, hypotension.
• Sickle cell crises: in patients with sickle cell disorders, sometimes fatal.
• Capillary leak syndrome: characterized by hypotension, low serum albumin, edema, and hemoconcentration, which can be life-threatening if not promptly treated.
• Glomerulonephritis, cutaneous vasculitis, and (rarely) aortitis.

Pregnancy: Data on the use of Ropenia during human pregnancy have not shown a clear association with major birth defects, miscarriage, or adverse maternal/fetal outcomes, but data remain limited. Ropenia should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: Ropenia has been detected in human milk in limited case reports, without reported adverse effects in breastfed infants, and is not expected to be significantly absorbed orally by the infant. A physician should weigh the benefits of breastfeeding against the mother's clinical need for Ropenia before use during lactation.

Before and during treatment with Ropenia, the following precautions apply:

• Splenic rupture: Patients reporting left upper abdominal or shoulder pain should be evaluated promptly for an enlarged or ruptured spleen.
• Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress; discontinue Ropenia if ARDS is diagnosed.
• Serious allergic reactions: Permanently discontinue Ropenia in patients who develop a serious allergic reaction (see Contraindications).
• Sickle cell disorders: Use with caution in patients with sickle cell trait or disease; severe, sometimes fatal, sickle cell crises have occurred. Discontinue if a crisis develops.
• Capillary leak syndrome: Monitor for signs (hypotension, edema) especially with repeated cycles; manage promptly, which may require intensive supportive care.
• Timing with chemotherapy/radiation: Do not administer in the 24 hours before to 24 hours after cytotoxic chemotherapy; avoid concurrent radiation therapy.
• Potential for tumor growth stimulation: Because G-CSF receptors may be found on some tumor cells, a stimulatory effect on malignant cells cannot be excluded; use caution in myeloid malignancies.
• Monitoring: Regular complete blood counts (including platelet count) and monitoring of neutrophil counts are recommended during therapy to avoid excessive leukocytosis.
• Bone mineral density changes have been reported with long-term use in severe chronic neutropenia; monitor bone density in patients on prolonged therapy.

There is limited clinical experience with Ropenia overdose. Excessive doses may result in an exaggerated increase in white blood cell (neutrophil) count (leukocytosis) and associated bone pain or musculoskeletal symptoms. If an overdose of Ropenia is suspected, seek immediate medical attention or contact emergency services/poison control; the treating physician will monitor blood counts and manage symptoms supportively. Do not attempt to self-treat a suspected overdose at home.

Store Ropenia injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze; if accidentally frozen, allow the product to thaw in the refrigerator before use and discard if it has been frozen more than once. Unrefrigerated (room temperature) storage should be limited to the period specified by the manufacturer's product labeling (generally no more than a single 24-hour period) — do not use if this limit is exceeded. Keep out of reach of children. Do not shake vigorously. Discard any unused portion; do not reuse vials/syringes.

Renal impairment

No dose adjustment is required in patients with mild-to-moderate renal impairment based on available pharmacokinetic data; specific data in severe renal impairment are limited, so use with caution and physician monitoring.

Hepatic impairment

No specific dose adjustment guidance is established for hepatic impairment; use Ropenia with clinical judgment and monitoring in patients with significant hepatic dysfunction.

Elderly

Clinical studies of Ropenia have not identified differences in response between elderly and younger patients, but dosing should be individualized, generally starting at the low end of the dosing range with attention to concomitant organ function.

Sickle cell disorders

Use with caution; severe sickle cell crises have been reported (see Precautions and Warnings).

Duration of Ropenia therapy depends on the indication: for chemotherapy-induced neutropenia, treatment is typically continued daily until the expected neutrophil nadir has passed and the absolute neutrophil count has returned to a normal range (up to about 2 weeks); for peripheral blood progenitor cell mobilization, therapy is continued through the collection period; for severe chronic neutropenia, Ropenia is often used long-term (chronic daily or alternate-day administration) with the lowest effective dose determined by the treating physician, and periodic reassessment of continued need.

Granulocyte colony-stimulating factor (G-CSF); hematopoietic growth factor; biologic/biosimilar agent.

Filgrastim binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, activating intracellular signaling that stimulates the proliferation, differentiation, and maturation of neutrophil precursors, and enhances the functional activity (phagocytosis, chemotaxis) of mature circulating neutrophils, thereby increasing the neutrophil count available to combat infection.

Ropenia has been used in pediatric patients, most extensively in severe chronic neutropenia, where its safety and effectiveness have been demonstrated in children as young as a few months old using weight-based dosing similar to adults (6 mcg/kg twice daily for congenital neutropenia; 5 mcg/kg once daily for cyclic/idiopathic neutropenia), with dose individualized to clinical response. For chemotherapy-induced neutropenia and other oncology indications in children, use of Ropenia follows similar weight-based dosing principles as in adults under specialist supervision, though safety and efficacy have not been as extensively established for every pediatric indication. Long-term use in children should be monitored for growth parameters and bone density given reports of decreased bone density with prolonged therapy. Use in neonates and infants should be directed by a pediatric specialist.